Four Decades for Justice
Geoffrey G. Hu focuses on patent litigation on behalf of pharmaceutical, biotechnology, medical device and telecommunication companies.
Mr. Hu was born in Jilin City, China. He received a B.S. in Biochemistry from Peking University in 1994, a Ph.D. in Biochemistry from Rutgers the State University and the University of Medicine and Dentistry of New Jersey in 2000 and a J.D. from Columbia Law School in 2006 where he was a Harlan Fiske Stone Scholar and an articles editor of The Science & Technology Law Review. Mr. Hu joined Cravath in 2017. Prior to joining Cravath, he was a senior attorney at a law firm in New York, where his practice focused on litigating and advising clients in pharmaceutical, biotechnology, medical device and telecommunication industries on complex patent and IP issues.
Mr. Hu was born in Jilin City, China. He received a B.S. in Biochemistry from Peking University in 1994, a Ph.D. in Biochemistry from Rutgers the State University and the University of Medicine and Dentistry of New Jersey in 2000 and a J.D. from Columbia Law School in 2006 where he was a Harlan Fiske Stone Scholar and an articles editor of The Science & Technology Law Review. Mr. Hu joined Cravath in 2017. Prior to joining Cravath, he was a senior attorney at a law firm in New York, where his practice focused on litigating and advising clients in pharmaceutical, biotechnology, medical device and telecommunication industries on complex patent and IP issues.
The New York Intellectual Property Law Association
Deals & Cases
September 02, 2022
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Geoffrey G. Hu focuses on patent litigation on behalf of pharmaceutical, biotechnology, medical device and telecommunication companies.
Mr. Hu was born in Jilin City, China. He received a B.S. in Biochemistry from Peking University in 1994, a Ph.D. in Biochemistry from Rutgers the State University and the University of Medicine and Dentistry of New Jersey in 2000 and a J.D. from Columbia Law School in 2006 where he was a Harlan Fiske Stone Scholar and an articles editor of The Science & Technology Law Review. Mr. Hu joined Cravath in 2017. Prior to joining Cravath, he was a senior attorney at a law firm in New York, where his practice focused on litigating and advising clients in pharmaceutical, biotechnology, medical device and telecommunication industries on complex patent and IP issues.
Mr. Hu was born in Jilin City, China. He received a B.S. in Biochemistry from Peking University in 1994, a Ph.D. in Biochemistry from Rutgers the State University and the University of Medicine and Dentistry of New Jersey in 2000 and a J.D. from Columbia Law School in 2006 where he was a Harlan Fiske Stone Scholar and an articles editor of The Science & Technology Law Review. Mr. Hu joined Cravath in 2017. Prior to joining Cravath, he was a senior attorney at a law firm in New York, where his practice focused on litigating and advising clients in pharmaceutical, biotechnology, medical device and telecommunication industries on complex patent and IP issues.
The New York Intellectual Property Law Association
Deals & Cases
September 02, 2022
On September 1, 2022, Chief Administrative Law Judge D. Michael Chappell of the Federal Trade Commission (“FTC”) ruled in favor of Cravath client Illumina, rejecting the FTC’s challenge to Illumina’s $8 billion acquisition of GRAIL, which closed in August 2021.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.